ScoreWhy is Alnylam Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 10.6%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 885.89 MM
- NET PROFIT(HY) Higher at USD 370.49 MM
- ROCE(HY) Highest at 100.7%
2
With ROE of 45.14%, it has a attractive valuation with a 53.33 Price to Book Value
- Over the past year, while the stock has generated a return of -49.62%, its profits have risen by 431.7% ; the PEG ratio of the company is 0.3
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Alnylam Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Alnylam Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Alnylam Pharmaceuticals, Inc.
-49.62%
0.94
45.78%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
49.77%
EBIT Growth (5y)
21.11%
EBIT to Interest (avg)
-3.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
118
Industry P/E
Price to Book Value
53.33
EV to EBIT
83.59
EV to EBITDA
75.24
EV to Capital Employed
67.14
EV to Sales
11.29
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
80.33%
ROE (Latest)
45.14%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 885.89 MM
NET PROFIT(HY)
Higher at USD 370.49 MM
ROCE(HY)
Highest at 100.7%
INVENTORY TURNOVER RATIO(HY)
Highest at 11.58 times
CASH AND EQV(HY)
Highest at USD 6,317.37 MM
NET SALES(Q)
Highest at USD 1,290.95 MM
-10What is not working for the Company
INTEREST(Q)
At USD 82.05 MM has Grown at 18.42%
RAW MATERIAL COST(Y)
Grown by 5.76% (YoY
Here's what is working for Alnylam Pharmaceuticals, Inc.
Net Profit
At USD 370.49 MM has Grown at 846.86%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Profit
Higher at USD 370.49 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 11.58 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Operating Cash Flow
Highest at USD 885.89 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 1,290.95 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 1,290.95 MM has Grown at 20.45%
over average net sales of the previous four periods of USD 1,071.73 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Cash and Eqv
Highest at USD 6,317.37 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Alnylam Pharmaceuticals, Inc.
Interest
At USD 82.05 MM has Grown at 18.42%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Raw Material Cost
Grown by 5.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Non Operating Income
Highest at USD 0.16 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
